TW202210102A - 用於預測與靜脈內投與治療抗體有關之耐受性問題的模型 - Google Patents

用於預測與靜脈內投與治療抗體有關之耐受性問題的模型 Download PDF

Info

Publication number
TW202210102A
TW202210102A TW110120461A TW110120461A TW202210102A TW 202210102 A TW202210102 A TW 202210102A TW 110120461 A TW110120461 A TW 110120461A TW 110120461 A TW110120461 A TW 110120461A TW 202210102 A TW202210102 A TW 202210102A
Authority
TW
Taiwan
Prior art keywords
therapeutic
antibody
dose
administration
antibody molecule
Prior art date
Application number
TW110120461A
Other languages
English (en)
Chinese (zh)
Inventor
比約恩 弗朗德斯
琳達 莫騰森
英格麗 泰格
英格麗 卡爾森
Original Assignee
瑞典商生物創新國際有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20178287.7A external-priority patent/EP3919077A1/en
Application filed by 瑞典商生物創新國際有限公司 filed Critical 瑞典商生物創新國際有限公司
Publication of TW202210102A publication Critical patent/TW202210102A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
TW110120461A 2020-06-04 2021-06-04 用於預測與靜脈內投與治療抗體有關之耐受性問題的模型 TW202210102A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP20178287.7 2020-06-04
EP20178287.7A EP3919077A1 (en) 2020-06-04 2020-06-04 Model for prediction of tolerability issues in connection with intravenous administration of therapeutic antibodies
EP21163703 2021-03-19
EP21163703.8 2021-03-19

Publications (1)

Publication Number Publication Date
TW202210102A true TW202210102A (zh) 2022-03-16

Family

ID=76217874

Family Applications (3)

Application Number Title Priority Date Filing Date
TW110120461A TW202210102A (zh) 2020-06-04 2021-06-04 用於預測與靜脈內投與治療抗體有關之耐受性問題的模型
TW110120464A TW202210104A (zh) 2020-06-04 2021-06-04 皮下抗體調配物
TW110120463A TW202210103A (zh) 2020-06-04 2021-06-04 治療系統、方法及用途

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW110120464A TW202210104A (zh) 2020-06-04 2021-06-04 皮下抗體調配物
TW110120463A TW202210103A (zh) 2020-06-04 2021-06-04 治療系統、方法及用途

Country Status (12)

Country Link
US (2) US20230322933A1 (cg-RX-API-DMAC10.html)
EP (2) EP4161574A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023527926A (cg-RX-API-DMAC10.html)
KR (1) KR20230038180A (cg-RX-API-DMAC10.html)
CN (1) CN116322767A (cg-RX-API-DMAC10.html)
AU (1) AU2021286202A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022024745A2 (cg-RX-API-DMAC10.html)
CA (1) CA3185020A1 (cg-RX-API-DMAC10.html)
IL (1) IL298757A (cg-RX-API-DMAC10.html)
MX (1) MX2022015229A (cg-RX-API-DMAC10.html)
TW (3) TW202210102A (cg-RX-API-DMAC10.html)
WO (3) WO2021245233A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202342057A (zh) * 2022-02-07 2023-11-01 美商健生生物科技公司 用於減少用ｅｇｆｒ／ｍｅｔ雙特異性抗體治療之患者的輸注相關反應之方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243706A (en) 1991-07-25 1994-08-26 Idec Pharma Corp Recombinant monkey antibodies, pharmaceutical compositions
US8187593B2 (en) * 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
MX2012004406A (es) * 2009-10-21 2012-05-08 Immunogen Inc Nuevo regimen de dosificacion y metodo de tratamiento.
GB201013989D0 (en) 2010-08-20 2010-10-06 Univ Southampton Biological materials and methods of using the same
GB2526139A (en) 2014-05-15 2015-11-18 Biolnvent Internat Ab Medicaments, uses and methods
CN108602889A (zh) * 2015-12-22 2018-09-28 瑞泽恩制药公司 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体
WO2019081983A1 (en) * 2017-10-25 2019-05-02 Novartis Ag CD32B TARGETING ANTIBODIES AND METHODS OF USE
JP7800852B2 (ja) 2018-01-10 2026-01-16 バイオインヴェント インターナショナル アーベー 抗体の新規組み合わせおよびその使用
EA202190102A1 (ru) 2018-08-16 2021-07-29 Генмаб А/С Коньюгаты антител к тканевым факторам с лекарственным средством и их применение в лечении рака
ES3009025T3 (en) 2018-08-31 2025-03-25 Regeneron Pharma Dosing strategy that mitigates cytokine release syndrome for cd3/cd20 bispecific antibodies

Also Published As

Publication number Publication date
JP2023527926A (ja) 2023-06-30
IL298757A (en) 2023-02-01
EP4161573A1 (en) 2023-04-12
BR112022024745A2 (pt) 2023-03-07
KR20230038180A (ko) 2023-03-17
AU2021286202A1 (en) 2023-01-19
TW202210104A (zh) 2022-03-16
CA3185020A1 (en) 2021-12-09
WO2021245238A9 (en) 2023-02-02
CN116322767A (zh) 2023-06-23
WO2021245238A1 (en) 2021-12-09
TW202210103A (zh) 2022-03-16
EP4161574A1 (en) 2023-04-12
WO2021245237A1 (en) 2021-12-09
US20240301070A1 (en) 2024-09-12
MX2022015229A (es) 2023-02-09
WO2021245233A1 (en) 2021-12-09
US20230322933A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
US12110337B2 (en) Anti-CD27 antibodies and uses thereof
KR20220163516A (ko) 인간화된, 마우스 또는 키메라 항-cd47 단클론 항체
CA3078605A1 (en) Tim-3 antagonists for the treatment and diagnosis of cancers
JP2023525085A (ja) がんを治療するための組成物および方法
US20220259309A1 (en) Antibody combinations for treatment of cancer in specific patients
KR20250018167A (ko) April에 대한 항체 분자 및 이의 용도
US20240209091A1 (en) Methods for treating cancer using anti-ctla4 antibodies
KR20240038769A (ko) 항-ilt3 항체를 사용하여 급성 골수성 백혈병을 치료하는 방법
TW202210103A (zh) 治療系統、方法及用途
RU2849966C1 (ru) Улучшение переносимости антител, связанной с внутривенным введением
JP2023545983A (ja) リンパ系悪性腫瘍状態の二重特異性抗体治療
US20240092912A1 (en) Novel combinations of antibodies and uses thereof
HK40087544A (zh) 改善与静脉内施用有关的抗体耐受性
US20260125486A1 (en) Methods and compositions for cancer treatment
EP3919077A1 (en) Model for prediction of tolerability issues in connection with intravenous administration of therapeutic antibodies
US20260000760A1 (en) Triple combination cancer therapy with anti-pvrig antibodies, anti-tigit antibodies, and pembrolizumab
HK40111402A (en) Novel combinations of antibodies and uses thereof
CA3236735A1 (en) Methods of treating cancer with a combination of an anti-pd-1 antibody and an anti-cd30 antibody-drug conjugate
HK40095521A (en) Novel combinations of antibodies and uses thereof
TW202336033A (zh) 抗體之新穎組合及用途